7RF

(6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate

Created: 2021-10-14
Last modified:  2022-11-23

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count0
Bond Count45
Aromatic Bond Count17
2D diagram of 7RF
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate
Systematic Name (OpenEye OEToolkits)(6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate
FormulaC19 H17 N5 O2
Molecular Weight347.371
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESCACTVS3.385NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc3cc(ccc3c2)C(N)=N
SMILESOpenEye OEToolkits2.0.7c1cc(ccc1C(=O)Oc2ccc3cc(ccc3c2)C(=N)N)NC(=N)N
Canonical SMILESCACTVS3.385 NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc3cc(ccc3c2)C(N)=N
Canonical SMILESOpenEye OEToolkits2.0.7 [H]/N=C(\c1ccc2cc(ccc2c1)OC(=O)c3ccc(cc3)N/C(=N/[H])/N)/N
InChIInChI1.03 InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
InChIKeyInChI1.03 MQQNFDZXWVTQEH-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB12598 
NameNafamostat
Groups investigational
DescriptionNafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
Synonyms
  • p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine
  • Nafamostat mesylate
  • Nafamostatum
  • Nafamostat
IndicationUsed as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.
Categories
  • Amidines
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents
  • Anticoagulants
CAS number81525-10-2

Drug Targets

NameTarget SequencePharmacological ActionActions
ProthrombinMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEE...unknowninhibitor
Coagulation factor XMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKK...unknowninhibitor
Coagulation factor XIIMRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFP...unknowninhibitor
Trypsin-1MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGG...unknowninhibitor
Kallikrein-1MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQC...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL273264
PubChem 4413
ChEMBL CHEMBL273264
ChEBI CHEBI:135466
CCDC/CSD HAMJAK